898.7500 11.40 (1.28%)
NSE Jun 27, 2025 15:31 PM
Volume: 668.4K
 

898.75
1.28%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading below its 200 day SMA of 927.7
More from Strides Pharma Science Ltd.
Recommended